🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the effort against drug-resistant strains of the bacteria, according to health experts.

An International Public Health Issue

Cases of gonorrhoea are escalating worldwide, with figures suggesting in excess of 82 million infections annually. Especially elevated rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Secure Clearance

One new antibiotic, alternatively called a brand name, was cleared by the US FDA in December for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This authorization represents a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Data and Global Access

Based on data published in a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which involves two antibiotics. The trial involved nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the ability to register and commercialise the drug in many regions with limited resources.

Medical professionals treating patients have voiced positive views. Access to a single-dose, oral treatment such as this is seen as a "critical tool" for public health efforts. This is viewed as crucial to lessen the impact of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea globally.